INM
Income statement / Annual
Last year (2024), InMed Pharmaceuticals Inc.'s total revenue was $4.60 M,
an increase of 11.18% from the previous year.
In 2024, InMed Pharmaceuticals Inc.'s net income was -$7.68 M.
See InMed Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$4.60 M |
$4.14 M |
$1.09 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.50 M
|
$2.73 M
|
$545,889.00
|
$197,031.00
|
$183,090.00
|
$93,940.00
|
$92,777.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$1.10 M
|
$1.40 M
|
$543,546.00
|
-$197,031.00
|
-$183,090.00
|
-$93,940.00
|
-$92,777.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.24
|
0.34
|
0.5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$3.77 M
|
$3.73 M
|
$7.28 M
|
$5.34 M
|
$5.20 M
|
$4.30 M
|
$1.52 M
|
$573,723.00
|
$292,840.00
|
$759,851.00
|
| General & Administrative Expenses |
$5.25 B
|
$5.85 M
|
$6.87 M
|
$4.48 M
|
$3.50 M
|
$6.00 M
|
$0.00
|
$2.79 M
|
$1.48 M
|
$2.62 M
|
| Selling & Marketing Expenses |
-$5.25 B
|
$0.00
|
$0.00
|
$0.00
|
$474,943.00
|
$706,229.00
|
$0.00
|
$844,275.00
|
$112,640.00
|
$498,436.00
|
| Selling, General & Administrative Expenses |
$5.25 M
|
$5.85 M
|
$6.87 M
|
$4.48 M
|
$3.50 M
|
$6.00 M
|
$5.17 M
|
$2.79 M
|
$1.48 M
|
$2.62 M
|
| Other Expenses |
$0.00
|
-$308,940.00
|
$185,657.00
|
$120,866.00
|
$161,969.00
|
$94,716.00
|
-$0.00
|
$75,216.00
|
$67,408.00
|
$75,757.00
|
| Operating Expenses |
$9.02 B
|
$9.78 M
|
$14.34 M
|
$9.94 M
|
$8.87 M
|
$10.39 M
|
$6.69 M
|
$3.44 M
|
$1.84 M
|
$3.46 M
|
| Cost And Expenses |
$16.01 B
|
$12.51 M
|
$14.88 M
|
$9.94 M
|
$8.87 M
|
$10.39 M
|
$6.78 M
|
$3.44 M
|
$1.84 M
|
$3.46 M
|
| Interest Income |
$527,901.00
|
$492,440.00
|
$96,090.00
|
$16,017.00
|
$125,885.00
|
$330,441.00
|
$69,546.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$96,090.00
|
$360,350.00
|
$18,616.00
|
$0.00
|
$0.00
|
$495.17
|
$47.92
|
$3,525.31
|
| Depreciation & Amortization |
$604,518.00
|
$595,997.00
|
$511,787.00
|
$197,031.00
|
$183,090.00
|
$94,716.00
|
$89,602.00
|
$75,216.00
|
$67,408.00
|
$75,757.00
|
| EBITDA |
-$7.06 M |
-$10.83 M |
-$17.26 M |
-$9.80 M |
-$8.58 M |
-$10.26 M |
-$6.69 M |
-$3.36 M |
-$1.77 M |
-$3.38 M |
| EBITDA Ratio |
-1.54
|
-2.62
|
-15.84
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-1977.13
|
-12.57
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$246.38 M
|
$588,531.00
|
-$1.10 M
|
$2.12 M
|
$60,733.00
|
$262,101.00
|
$69,774.00
|
-$495.17
|
-$47.92
|
-$3,525.31
|
| Income Before Tax |
-$7.67 M
|
-$7.93 M
|
-$18.60 M
|
-$10.20 M
|
-$8.68 M
|
-$10.10 M
|
-$6.71 M
|
-$3.44 M
|
-$1.84 M
|
-$3.46 M
|
| Income Before Tax Ratio |
-1.67
|
-1.92
|
-17.07
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$7,100.00
|
$13,100.00
|
$4.81 M
|
$360,350.00
|
$18,616.00
|
-$262,101.61
|
-$69,542.00
|
$495.17
|
$47.92
|
$3,525.31
|
| Net Income |
-$7.68 M
|
-$7.95 M
|
-$18.60 M
|
-$10.20 M
|
-$8.94 M
|
-$10.01 M
|
-$6.71 M
|
-$3.44 M
|
-$1.84 M
|
-$3.46 M
|
| Net Income Ratio |
-1.67
|
-1.92
|
-17.07
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.0071 |
-4.3 |
-42.69 |
-47.06 |
-58.11 |
-64.01 |
-49.35 |
-41.26 |
-32.58 |
-76.83 |
| EPS Diluted |
-1.0071 |
-4.31 |
-42.7 |
-47.06 |
-58.11 |
-64.01 |
-49.35 |
-41.26 |
-32.58 |
-76.83 |
| Weighted Average Shares Out |
$7.62 M
|
$2.45 M
|
$560,751.00
|
$268,792.00
|
$208,827.00
|
$207,092.00
|
$172,669.00
|
$108,427.00
|
$72,966.00
|
$55,872.00
|
| Weighted Average Shares Out Diluted |
$7.62 M
|
$2.45 M
|
$560,829.00
|
$268,793.00
|
$208,828.00
|
$207,092.00
|
$172,669.00
|
$108,427.00
|
$72,966.00
|
$55,872.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
